批准日期,申请提交历史,通知信,药品说明书,审评文件等信息
提交状态日期 | 提交号 | 审批结论 | 申请内容分类 | 审评优先级;罕用药状态 | 通知信、审评文件、说明书、包装标签 | 备注 |
2021/08/30 |
SUPPL-39(补充) |
Approval |
Efficacy |
STANDARD
|
|
|
2020/08/14 |
SUPPL-37(补充) |
Approval |
Labeling |
STANDARD
|
|
|
2020/07/10 |
SUPPL-38(补充) |
Approval |
Labeling |
STANDARD
|
|
|
2019/05/07 |
SUPPL-36(补充) |
Approval |
Efficacy |
PRIORITY
|
|
|
2018/12/13 |
SUPPL-35(补充) |
Approval |
Labeling |
STANDARD
|
|
|
2017/11/16 |
SUPPL-33(补充) |
Approval |
Efficacy |
STANDARD
|
|
|
2015/11/16 |
SUPPL-31(补充) |
Approval |
Labeling |
STANDARD
|
|
|
2015/10/08 |
SUPPL-30(补充) |
Approval |
Manufacturing (CMC) |
PRIORITY
|
|
|
2015/04/24 |
SUPPL-29(补充) |
Approval |
Labeling |
STANDARD
|
|
|
2015/04/24 |
SUPPL-28(补充) |
Approval |
Labeling |
STANDARD
|
|
|
2014/12/19 |
SUPPL-27(补充) |
Approval |
Labeling |
STANDARD
|
|
|
2014/06/11 |
SUPPL-26(补充) |
Approval |
Labeling |
STANDARD
|
|
|
2013/08/30 |
SUPPL-25(补充) |
Approval |
Labeling |
STANDARD
|
|
|
2013/08/30 |
SUPPL-24(补充) |
Approval |
Labeling |
STANDARD
|
|
|
2012/11/16 |
SUPPL-23(补充) |
Approval |
Labeling |
STANDARD
|
|
|
2012/11/16 |
SUPPL-22(补充) |
Approval |
Labeling |
STANDARD
|
|
|
2012/11/16 |
SUPPL-21(补充) |
Approval |
Labeling |
STANDARD
|
|
|
2012/04/20 |
SUPPL-20(补充) |
Approval |
Labeling |
UNKNOWN
|
|
|
2012/04/20 |
SUPPL-19(补充) |
Approval |
Labeling |
UNKNOWN
|
|
|
2011/05/20 |
SUPPL-18(补充) |
Approval |
Labeling |
UNKNOWN
|
|
|
2011/05/20 |
SUPPL-17(补充) |
Approval |
Labeling |
STANDARD
|
|
|
2011/05/20 |
SUPPL-13(补充) |
Approval |
Efficacy |
PRIORITY
|
|
|
2010/07/01 |
SUPPL-15(补充) |
Approval |
Labeling |
901 REQUIRED
|
|
|
2010/07/01 |
SUPPL-14(补充) |
Approval |
Labeling |
UNKNOWN
|
|
|
2010/07/01 |
SUPPL-11(补充) |
Approval |
Labeling |
UNKNOWN
|
|
|
2010/07/01 |
SUPPL-10(补充) |
Approval |
Efficacy |
STANDARD
|
|
|
2009/03/31 |
SUPPL-9(补充) |
Approval |
Manufacturing (CMC) |
N/A
|
|
|
2008/11/07 |
SUPPL-8(补充) |
Approval |
Labeling |
STANDARD
|
|
|
2008/11/07 |
SUPPL-7(补充) |
Approval |
Labeling |
STANDARD
|
|
|
2008/11/07 |
SUPPL-6(补充) |
Approval |
Labeling |
STANDARD
|
|
|
2007/02/02 |
SUPPL-5(补充) |
Approval |
Efficacy |
PRIORITY
|
|
|
2007/02/02 |
SUPPL-4(补充) |
Approval |
Efficacy |
PRIORITY
|
|
|
2007/02/02 |
SUPPL-3(补充) |
Approval |
Efficacy |
UNKNOWN
|
|
|
2007/02/02 |
SUPPL-2(补充) |
Approval |
Labeling |
STANDARD
|
|
|
2006/05/10 |
SUPPL-1(补充) |
Approval |
Manufacturing (CMC) |
N/A
|
|
|
2006/01/26 |
ORIG-1(原始申请) |
Approval |
Type 1 - New Molecular Entity |
PRIORITY
|
|
|
与本品相关的专利信息(来自FDA橙皮书Orange Book)
与本品治疗等效的药品
活性成分:SUNITINIB MALATE 剂型/给药途径:CAPSULE;ORAL 规格:EQ 12.5MG BASE 治疗等效代码:AB
申请号 | 产品号 | 申请类型 | 商品名 | 活性成分 | 剂型/给药途径 | 规格 | 市场状态 | RLD | RS | TE Code | 产品号批准日期 | 申请人 |
021938 |
001 |
NDA |
SUTENT |
SUNITINIB MALATE |
CAPSULE;ORAL |
EQ 12.5MG BASE |
Prescription |
Yes |
No |
AB |
2006/01/26
|
CPPI CV |
213914 |
001 |
ANDA |
SUNITINIB MALATE |
SUNITINIB MALATE |
CAPSULE;ORAL |
EQ 12.5MG BASE |
Prescription |
No |
No |
AB |
2021/08/16
|
SUN PHARM |
213803 |
001 |
ANDA |
SUNITINIB MALATE |
SUNITINIB MALATE |
CAPSULE;ORAL |
EQ 12.5MG BASE |
Prescription |
No |
No |
AB |
2021/11/30
|
TEVA PHARMS USA |
201275 |
001 |
ANDA |
SUNITINIB MALATE |
SUNITINIB MALATE |
CAPSULE;ORAL |
EQ 12.5MG BASE |
Prescription |
No |
No |
AB |
2021/12/06
|
MYLAN |
215843 |
001 |
ANDA |
SUNITINIB MALATE |
SUNITINIB MALATE |
CAPSULE;ORAL |
EQ 12.5MG BASE |
Prescription |
No |
No |
AB |
2022/04/11
|
DR REDDYS |
218012 |
001 |
ANDA |
SUNITINIB MALATE |
SUNITINIB MALATE |
CAPSULE;ORAL |
EQ 12.5MG BASE |
Prescription |
No |
No |
AB |
2023/08/21
|
WANBANG BIOPHARMS |
218024 |
001 |
ANDA |
SUNITINIB MALATE |
SUNITINIB MALATE |
CAPSULE;ORAL |
EQ 12.5MG BASE |
Prescription |
No |
No |
AB |
2023/10/24
|
NATCO PHARMA |
218615 |
001 |
ANDA |
SUNITINIB MALATE |
SUNITINIB MALATE |
CAPSULE;ORAL |
EQ 12.5MG BASE |
Prescription |
No |
No |
AB |
2024/03/14
|
EUGIA PHARMA |
活性成分:SUNITINIB MALATE 剂型/给药途径:CAPSULE;ORAL 规格:EQ 25MG BASE 治疗等效代码:AB
申请号 | 产品号 | 申请类型 | 商品名 | 活性成分 | 剂型/给药途径 | 规格 | 市场状态 | RLD | RS | TE Code | 产品号批准日期 | 申请人 |
021938 |
002 |
NDA |
SUTENT |
SUNITINIB MALATE |
CAPSULE;ORAL |
EQ 25MG BASE |
Prescription |
Yes |
No |
AB |
2006/01/26
|
CPPI CV |
213914 |
002 |
ANDA |
SUNITINIB MALATE |
SUNITINIB MALATE |
CAPSULE;ORAL |
EQ 25MG BASE |
Prescription |
No |
No |
AB |
2021/08/16
|
SUN PHARM |
213803 |
002 |
ANDA |
SUNITINIB MALATE |
SUNITINIB MALATE |
CAPSULE;ORAL |
EQ 25MG BASE |
Prescription |
No |
No |
AB |
2021/11/30
|
TEVA PHARMS USA |
201275 |
002 |
ANDA |
SUNITINIB MALATE |
SUNITINIB MALATE |
CAPSULE;ORAL |
EQ 25MG BASE |
Prescription |
No |
No |
AB |
2021/12/06
|
MYLAN |
215843 |
002 |
ANDA |
SUNITINIB MALATE |
SUNITINIB MALATE |
CAPSULE;ORAL |
EQ 25MG BASE |
Prescription |
No |
No |
AB |
2022/04/11
|
DR REDDYS |
218012 |
002 |
ANDA |
SUNITINIB MALATE |
SUNITINIB MALATE |
CAPSULE;ORAL |
EQ 25MG BASE |
Prescription |
No |
No |
AB |
2023/08/21
|
WANBANG BIOPHARMS |
218024 |
002 |
ANDA |
SUNITINIB MALATE |
SUNITINIB MALATE |
CAPSULE;ORAL |
EQ 25MG BASE |
Prescription |
No |
No |
AB |
2023/10/24
|
NATCO PHARMA |
218615 |
002 |
ANDA |
SUNITINIB MALATE |
SUNITINIB MALATE |
CAPSULE;ORAL |
EQ 25MG BASE |
Prescription |
No |
No |
AB |
2024/03/14
|
EUGIA PHARMA |
活性成分:SUNITINIB MALATE 剂型/给药途径:CAPSULE;ORAL 规格:EQ 50MG BASE 治疗等效代码:AB
申请号 | 产品号 | 申请类型 | 商品名 | 活性成分 | 剂型/给药途径 | 规格 | 市场状态 | RLD | RS | TE Code | 产品号批准日期 | 申请人 |
021938 |
003 |
NDA |
SUTENT |
SUNITINIB MALATE |
CAPSULE;ORAL |
EQ 50MG BASE |
Prescription |
Yes |
Yes |
AB |
2006/01/26
|
CPPI CV |
213914 |
004 |
ANDA |
SUNITINIB MALATE |
SUNITINIB MALATE |
CAPSULE;ORAL |
EQ 50MG BASE |
Prescription |
No |
No |
AB |
2021/08/16
|
SUN PHARM |
213803 |
004 |
ANDA |
SUNITINIB MALATE |
SUNITINIB MALATE |
CAPSULE;ORAL |
EQ 50MG BASE |
Prescription |
No |
No |
AB |
2021/11/30
|
TEVA PHARMS USA |
201275 |
004 |
ANDA |
SUNITINIB MALATE |
SUNITINIB MALATE |
CAPSULE;ORAL |
EQ 50MG BASE |
Prescription |
No |
No |
AB |
2021/12/06
|
MYLAN |
215843 |
004 |
ANDA |
SUNITINIB MALATE |
SUNITINIB MALATE |
CAPSULE;ORAL |
EQ 50MG BASE |
Prescription |
No |
No |
AB |
2022/04/11
|
DR REDDYS |
218012 |
004 |
ANDA |
SUNITINIB MALATE |
SUNITINIB MALATE |
CAPSULE;ORAL |
EQ 50MG BASE |
Prescription |
No |
No |
AB |
2023/08/21
|
WANBANG BIOPHARMS |
218024 |
004 |
ANDA |
SUNITINIB MALATE |
SUNITINIB MALATE |
CAPSULE;ORAL |
EQ 50MG BASE |
Prescription |
No |
No |
AB |
2023/10/24
|
NATCO PHARMA |
218615 |
004 |
ANDA |
SUNITINIB MALATE |
SUNITINIB MALATE |
CAPSULE;ORAL |
EQ 50MG BASE |
Prescription |
No |
No |
AB |
2024/03/14
|
EUGIA PHARMA |
活性成分:SUNITINIB MALATE 剂型/给药途径:CAPSULE;ORAL 规格:EQ 37.5MG BASE 治疗等效代码:AB
申请号 | 产品号 | 申请类型 | 商品名 | 活性成分 | 剂型/给药途径 | 规格 | 市场状态 | RLD | RS | TE Code | 产品号批准日期 | 申请人 |
021938 |
004 |
NDA |
SUTENT |
SUNITINIB MALATE |
CAPSULE;ORAL |
EQ 37.5MG BASE |
Prescription |
Yes |
No |
AB |
2009/03/31
|
CPPI CV |
213914 |
003 |
ANDA |
SUNITINIB MALATE |
SUNITINIB MALATE |
CAPSULE;ORAL |
EQ 37.5MG BASE |
Prescription |
No |
No |
AB |
2021/08/16
|
SUN PHARM |
213803 |
003 |
ANDA |
SUNITINIB MALATE |
SUNITINIB MALATE |
CAPSULE;ORAL |
EQ 37.5MG BASE |
Prescription |
No |
No |
AB |
2021/11/30
|
TEVA PHARMS USA |
201275 |
003 |
ANDA |
SUNITINIB MALATE |
SUNITINIB MALATE |
CAPSULE;ORAL |
EQ 37.5MG BASE |
Prescription |
No |
No |
AB |
2021/12/06
|
MYLAN |
215843 |
003 |
ANDA |
SUNITINIB MALATE |
SUNITINIB MALATE |
CAPSULE;ORAL |
EQ 37.5MG BASE |
Prescription |
No |
No |
AB |
2022/04/11
|
DR REDDYS |
218012 |
003 |
ANDA |
SUNITINIB MALATE |
SUNITINIB MALATE |
CAPSULE;ORAL |
EQ 37.5MG BASE |
Prescription |
No |
No |
AB |
2023/08/21
|
WANBANG BIOPHARMS |
218024 |
003 |
ANDA |
SUNITINIB MALATE |
SUNITINIB MALATE |
CAPSULE;ORAL |
EQ 37.5MG BASE |
Prescription |
No |
No |
AB |
2023/10/24
|
NATCO PHARMA |
218615 |
003 |
ANDA |
SUNITINIB MALATE |
SUNITINIB MALATE |
CAPSULE;ORAL |
EQ 37.5MG BASE |
Prescription |
No |
No |
AB |
2024/03/14
|
EUGIA PHARMA |